AcelRx Pharmaceuticals Inc(NASDAQ:ACRX) reported the income comes about for Fiscal Year 2016 and Q3. The outcomes came in amid After-hours on Nov 1, 2016. Organization reported income of $3.37M. Examiners assessed an income of $2.89M. The incomes were $476.00K or 16.47% over the appraisals. Profit per share were $-0.25. The reported EPS was underneath evaluations by $-0.02 or NaN%. Investigators had evaluated an EPS of $-0.23.
AcelRx Pharmaceuticals Inc (ACRX) offers turned negative on Fridays exchanging session with the shares shutting down - 0.05 focuses or - 1.67% at a volume of 2,33,839. The negative mind-set was apparent in the organization offers which never went impressively past the level of $3. The pinnacle value level was additionally observed at $3 while the days least was $2.9. At long last the shares shut at $2.95. The 52-week high of the shares is $5.88 while the 52-week low is $2.4. As indicated by the most recent data accessible, the market top of the organization is $134 M.
A few Insider Transactions has been accounted for to the SEC. On May 16, 2016, Howard B Rosen (CEO) bought 10,206 shares at $3.26 per share price.Also, On May 12, 2016, Mark G Edwards (chief) obtained 15,000 shares at $3.15 per share price.On Apr 23, 2015, Richard Afable (executive) acquired 1,000 shares at $10.30 per share cost, by Form-4 documenting with the securities and trade commission.
AcelRx Pharmaceuticals Inc. is an improvement arrange claim to fame pharmaceutical organization concentrated on the advancement and commercialization of treatments for the treatment of intense torment. The Company's lead item competitor Zalviso is proposed for the administration of direct to-extreme intense agony in hospitalized grown-up patients. Zalviso comprises of sufentanil sublingual tablets conveyed by the Zalviso System. The Company has three extra item competitors in clinical improvement: the Sufentanil Sublingual Tablet BTP Management System (ARX-02) a torment administration framework for the treatment of tumor patients who experience the ill effects of Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03) is a solitary settled measurement mix tranquilize item intended to give gentle sedation tension lessening and agony help and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of direct to-extreme intense torment.
AcelRx Pharmaceuticals Inc (ACRX) offers turned negative on Fridays exchanging session with the shares shutting down - 0.05 focuses or - 1.67% at a volume of 2,33,839. The negative mind-set was apparent in the organization offers which never went impressively past the level of $3. The pinnacle value level was additionally observed at $3 while the days least was $2.9. At long last the shares shut at $2.95. The 52-week high of the shares is $5.88 while the 52-week low is $2.4. As indicated by the most recent data accessible, the market top of the organization is $134 M.
A few Insider Transactions has been accounted for to the SEC. On May 16, 2016, Howard B Rosen (CEO) bought 10,206 shares at $3.26 per share price.Also, On May 12, 2016, Mark G Edwards (chief) obtained 15,000 shares at $3.15 per share price.On Apr 23, 2015, Richard Afable (executive) acquired 1,000 shares at $10.30 per share cost, by Form-4 documenting with the securities and trade commission.
AcelRx Pharmaceuticals Inc. is an improvement arrange claim to fame pharmaceutical organization concentrated on the advancement and commercialization of treatments for the treatment of intense torment. The Company's lead item competitor Zalviso is proposed for the administration of direct to-extreme intense agony in hospitalized grown-up patients. Zalviso comprises of sufentanil sublingual tablets conveyed by the Zalviso System. The Company has three extra item competitors in clinical improvement: the Sufentanil Sublingual Tablet BTP Management System (ARX-02) a torment administration framework for the treatment of tumor patients who experience the ill effects of Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03) is a solitary settled measurement mix tranquilize item intended to give gentle sedation tension lessening and agony help and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of direct to-extreme intense torment.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.